TCRT
Alaunos Therapeutics, Inc.
Price Chart
Latest Quote
$2.15
-0.07 (-3.15%)
Current Price
| Previous Close | $2.22 |
| Open | $2.20 |
| Day High | $2.23 |
| Day Low | $2.15 |
| Volume | 16,001 |
Stock Information
| Shares Outstanding | 2.44M |
| Cash Equivalents | $354K |
| Revenue | $3K |
| Net Income | $-4.21M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $5.25M |
| EPS (TTM) | $-2.12 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $5.07M |
| Sales | $3K |
| Income | $-4.21M |
| Book/sh | $1.27 |
| Cash/sh | $0.14 |
| Employees | 1 |
Financial Ratios
| Quick Ratio | 0.59 |
| Current Ratio | 1.63 |
Returns & Margins
| ROA | -129.43% |
| ROE | -350.30% |
| Operating Margin | -138166.67% |
Ownership
| Insider Ownership | 14.03% |
| Institutional Ownership | 6.53% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -3.58 |
| PEG | 0.58 |
| P/S | 1750.20 |
| P/B | 1.69 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $2.41 |
| SMA50 | $2.57 |
| SMA200 | $2.90 |
| RSI | 24.26 |
| ATR | 0.1764 |
| Shares Float | 1.91M |
| Short Float | 0.62% |
| Short Ratio | 0.94 |
| Volatility | -1.06 |
| Rel Volume | 0.74 |
Performance History
| Week | -2.71% |
| Month | -14.00% |
| Quarter | -35.05% |
| 6 Months | -50.69% |
| YTD | -34.45% |
| Year | -41.26% |
| 3 Years | -96.88% |
| 5 Years | -99.50% |
| 10 Years | -99.76% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $2.15 | 16,001 |
| 2026-06-17 | $2.22 | 1,300 |
| 2026-06-16 | $2.24 | 5,100 |
| 2026-06-15 | $2.28 | 11,000 |
| 2026-06-12 | $2.26 | 7,400 |
| 2026-06-11 | $2.21 | 20,900 |
| 2026-06-10 | $1.97 | 12,400 |
| 2026-06-09 | $1.99 | 27,000 |
| 2026-06-08 | $2.00 | 31,800 |
| 2026-06-05 | $2.28 | 42,600 |
| 2026-06-04 | $2.44 | 22,800 |
| 2026-06-03 | $2.62 | 36,300 |
| 2026-06-02 | $2.75 | 18,200 |
| 2026-06-01 | $2.87 | 10,800 |
| 2026-05-29 | $2.85 | 17,400 |
| 2026-05-28 | $3.06 | 33,000 |
| 2026-05-27 | $2.81 | 67,800 |
| 2026-05-26 | $2.45 | 22,000 |
| 2026-05-22 | $2.42 | 14,500 |
| 2026-05-21 | $2.37 | 11,900 |
| 2026-05-20 | $2.40 | 4,500 |
| 2026-05-19 | $2.50 | 20,100 |
About Alaunos Therapeutics, Inc.
Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is based in Fort Lauderdale, Florida.
đ° Latest News
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $5,000 | $10,000 | $5,000 | $2,922,000 |
| Operating Revenue | $5,000 | $10,000 | $5,000 | $2,922,000 |
| Expenses | ||||
| Total Expenses | $4,230,000 | $4,822,000 | $28,498,000 | $38,160,000 |
| Other Income Expense | $49,000 | $133,000 | $-4,726,000 | $662,000 |
| Other Non Operating Income Expenses | $80,000 | $133,000 | $1,048,000 | $529,000 |
| Operating Expense | $4,230,000 | $4,822,000 | $28,498,000 | $38,160,000 |
| General And Administrative Expense | $2,867,000 | $4,460,000 | $12,219,000 | $13,142,000 |
| Interest Expense | - | $0 | $1,921,000 | $3,154,000 |
| Net Non Operating Interest Income Expense | - | $0 | $-1,921,000 | $-3,154,000 |
| Interest Expense Non Operating | - | $0 | $1,921,000 | $3,154,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-4,176,000 | $-4,679,000 | $-35,140,000 | $-37,730,000 |
| Normalized Income | $-4,145,000 | $-4,679,000 | $-29,366,000 | $-37,863,000 |
| Net Income From Continuing And Discontinued Operation | $-4,176,000 | $-4,679,000 | $-35,140,000 | $-37,730,000 |
| Total Operating Income As Reported | $-4,225,000 | $-4,812,000 | $-34,267,000 | $-35,105,000 |
| Net Income Common Stockholders | $-4,176,000 | $-4,679,000 | $-35,140,000 | $-37,730,000 |
| Net Income | $-4,176,000 | $-4,679,000 | $-35,140,000 | $-37,730,000 |
| Net Income Including Noncontrolling Interests | $-4,176,000 | $-4,679,000 | $-35,140,000 | $-37,730,000 |
| Net Income Continuous Operations | $-4,176,000 | $-4,679,000 | $-35,140,000 | $-37,730,000 |
| Pretax Income | $-4,176,000 | $-4,679,000 | $-35,140,000 | $-37,730,000 |
| Operating Income | $-4,225,000 | $-4,812,000 | $-28,493,000 | $-35,238,000 |
| Net Interest Income | - | $0 | $-1,921,000 | $-3,154,000 |
| Special Income Charges | - | $0 | $-5,774,000 | $133,000 |
| Per Share | ||||
| Diluted EPS | $-2.20 | $-2.92 | $-21.97 | $-25.50 |
| Basic EPS | $-2.20 | $-2.92 | $-21.97 | $-25.50 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-4,187,000 | $-4,810,000 | $-25,130,000 | $-31,950,000 |
| Total Unusual Items | $-31,000 | $0 | $-5,774,000 | $133,000 |
| Total Unusual Items Excluding Goodwill | $-31,000 | $0 | $-5,774,000 | $133,000 |
| Reconciled Depreciation | $7,000 | $2,000 | $2,315,000 | $2,759,000 |
| EBITDA (Bullshit earnings) | $-4,218,000 | $-4,810,000 | $-30,904,000 | $-31,817,000 |
| EBIT | $-4,225,000 | $-4,812,000 | $-33,219,000 | $-34,576,000 |
| Diluted Average Shares | $1,948,357 | $1,601,252 | $1,599,532 | $1,447,535 |
| Basic Average Shares | $1,948,357 | $1,601,252 | $1,599,532 | $1,447,535 |
| Diluted NI Availto Com Stockholders | $-4,176,000 | $-4,679,000 | $-35,140,000 | $-37,730,000 |
| Gain On Sale Of Security | $-31,000 | - | - | - |
| Research And Development | $1,363,000 | $362,000 | $16,279,000 | $25,018,000 |
| Selling General And Administration | $2,867,000 | $4,460,000 | $12,219,000 | $13,142,000 |
| Other Gand A | $2,867,000 | $4,460,000 | $12,219,000 | $13,142,000 |
| Impairment Of Capital Assets | - | $0 | $4,803,000 | $0 |
| Restructuring And Mergern Acquisition | - | $0 | $1,269,000 | $0 |
| Other Special Charges | - | - | $-298,000 | $-133,000 |
Fetched: 2026-06-13
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $2,153,000 | $2,063,000 | $6,307,000 | $38,555,000 |
| Total Assets | $2,966,000 | $2,755,000 | $8,263,000 | $64,937,000 |
| Total Non Current Assets | $978,000 | $0 | $2,000 | $11,138,000 |
| Other Non Current Assets | $887,000 | - | - | $500,000 |
| Current Assets | $1,988,000 | $2,755,000 | $8,261,000 | $53,799,000 |
| Other Current Assets | $600,000 | $1,659,000 | $2,198,000 | $799,000 |
| Receivables | $3,000 | $5,000 | $1,000 | $4,000 |
| Accounts Receivable | $3,000 | $5,000 | $1,000 | $4,000 |
| Cash Cash Equivalents And Short Term Investments | $1,385,000 | $1,091,000 | $6,062,000 | $39,058,000 |
| Cash And Cash Equivalents | $1,385,000 | $1,091,000 | $6,062,000 | $39,058,000 |
| Non Current Prepaid Assets | - | - | $0 | $42,000 |
| Restricted Cash | - | - | $0 | $13,938,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | - | - | $0 | $19,511,000 |
| Long Term Debt And Capital Lease Obligation | - | - | $0 | $2,188,000 |
| Current Debt And Capital Lease Obligation | - | - | - | $17,323,000 |
| Current Debt | - | - | - | $16,765,000 |
| Other Current Borrowings | - | - | - | $16,765,000 |
| Long Term Debt | - | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $813,000 | $692,000 | $1,956,000 | $26,382,000 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 | $2,216,000 |
| Current Liabilities | $813,000 | $692,000 | $1,956,000 | $24,166,000 |
| Payables And Accrued Expenses | $813,000 | $692,000 | $1,913,000 | $5,683,000 |
| Payables | $667,000 | $516,000 | $616,000 | $1,389,000 |
| Total Tax Payable | $54,000 | $0 | - | - |
| Accounts Payable | $613,000 | $516,000 | $616,000 | $1,389,000 |
| Other Non Current Liabilities | - | - | - | $28,000 |
| Equity | ||||
| Common Stock Equity | $2,153,000 | $2,063,000 | $6,307,000 | $38,555,000 |
| Total Equity Gross Minority Interest | $2,153,000 | $2,063,000 | $6,307,000 | $38,555,000 |
| Stockholders Equity | $2,153,000 | $2,063,000 | $6,307,000 | $38,555,000 |
| Retained Earnings | $-924,622,000 | $-920,446,000 | $-915,767,000 | $-880,627,000 |
| Other | ||||
| Ordinary Shares Number | $2,349,480 | $1,601,252 | $1,601,252 | $1,602,738 |
| Share Issued | $2,349,480 | $1,601,252 | $1,601,252 | $1,602,738 |
| Tangible Book Value | $2,153,000 | $2,063,000 | $6,307,000 | $38,555,000 |
| Invested Capital | $2,153,000 | $2,063,000 | $6,307,000 | $55,320,000 |
| Working Capital | $1,175,000 | $2,063,000 | $6,305,000 | $29,633,000 |
| Total Capitalization | $2,153,000 | $2,063,000 | $6,307,000 | $38,555,000 |
| Additional Paid In Capital | $926,773,000 | $922,507,000 | $922,072,000 | $919,166,000 |
| Capital Stock | $2,000 | $2,000 | $2,000 | $16,000 |
| Common Stock | $2,000 | $2,000 | $2,000 | $16,000 |
| Preferred Stock | $0 | $0 | - | - |
| Current Accrued Expenses | $146,000 | $176,000 | $1,297,000 | $4,294,000 |
| Net PPE | $91,000 | $0 | $2,000 | $10,596,000 |
| Accumulated Depreciation | $-7,000 | $-15,000 | $-13,000 | $-9,807,000 |
| Gross PPE | $98,000 | $15,000 | $15,000 | $20,403,000 |
| Other Properties | $98,000 | - | - | $5,232,000 |
| Machinery Furniture Equipment | $0 | $15,000 | $15,000 | $3,474,000 |
| Pensionand Other Post Retirement Benefit Plans Current | - | $0 | $43,000 | $1,160,000 |
| Capital Lease Obligations | - | - | $0 | $2,746,000 |
| Long Term Capital Lease Obligation | - | - | $0 | $2,188,000 |
| Current Capital Lease Obligation | - | - | $0 | $558,000 |
| Leases | - | - | $0 | $9,561,000 |
| Buildings And Improvements | - | - | $0 | $2,136,000 |
| Properties | - | - | $0 | $0 |
| Construction In Progress | - | - | - | $5,232,000 |
Fetched: 2026-06-13
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-2,967,000 | $-4,971,000 | $-30,339,000 | $-29,448,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-2,869,000 | $-4,971,000 | $-30,142,000 | $-29,232,000 |
| Cash Flow From Continuing Operating Activities | $-2,869,000 | $-4,971,000 | $-30,142,000 | $-29,232,000 |
| Operating Gains Losses | $31,000 | - | $7,000 | $7,000 |
| Investing Activities | ||||
| Capital Expenditure | $-98,000 | - | $-197,000 | $-216,000 |
| Cash Flow From Continuing Investing Activities | $-98,000 | $0 | $1,346,000 | $-193,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $3,261,000 | $0 | $92,000 | $14,724,000 |
| Financing Cash Flow | $3,261,000 | $0 | $-18,138,000 | $6,367,000 |
| Cash Flow From Continuing Financing Activities | $3,261,000 | $0 | $-18,138,000 | $6,367,000 |
| Net Preferred Stock Issuance | $1,350,000 | $0 | - | - |
| Preferred Stock Issuance | $1,350,000 | $0 | - | - |
| Net Common Stock Issuance | $1,911,000 | $0 | $92,000 | $14,679,000 |
| Common Stock Issuance | $1,911,000 | $0 | $92,000 | $14,724,000 |
| Repurchase Of Capital Stock | - | - | $0 | $-45,000 |
| Net Other Financing Charges | - | - | $-125,000 | - |
| Other | ||||
| Interest Paid Supplemental Data | $0 | $0 | $2,063,000 | $2,171,000 |
| End Cash Position | $1,385,000 | $1,091,000 | $6,062,000 | $52,996,000 |
| Beginning Cash Position | $1,091,000 | $6,062,000 | $52,996,000 | $76,054,000 |
| Changes In Cash | $294,000 | $-4,971,000 | $-46,934,000 | $-23,058,000 |
| Net PPE Purchase And Sale | $-98,000 | $0 | $1,346,000 | $-193,000 |
| Purchase Of PPE | $-98,000 | $0 | $-197,000 | $-216,000 |
| Change In Working Capital | $473,000 | $-729,000 | $-6,254,000 | $870,000 |
| Change In Payables And Accrued Expense | $121,000 | $-1,264,000 | $-4,762,000 | $-693,000 |
| Change In Accrued Expense | $24,000 | $-1,164,000 | $-3,989,000 | $-668,000 |
| Change In Payable | $97,000 | $-100,000 | $-773,000 | $-25,000 |
| Change In Account Payable | $97,000 | $-100,000 | $-773,000 | $-25,000 |
| Change In Prepaid Assets | $350,000 | $539,000 | $-1,357,000 | $867,000 |
| Change In Receivables | $2,000 | $-4,000 | $3,000 | $1,107,000 |
| Other Non Cash Items | $382,000 | - | $1,327,000 | $1,334,000 |
| Stock Based Compensation | $414,000 | $435,000 | $2,800,000 | $3,528,000 |
| Depreciation Amortization Depletion | $7,000 | $2,000 | $2,315,000 | $2,759,000 |
| Depreciation And Amortization | $7,000 | $2,000 | $2,315,000 | $2,759,000 |
| Depreciation | $7,000 | $2,000 | $2,315,000 | $2,759,000 |
| Gain Loss On Investment Securities | $31,000 | - | - | - |
| Net Income From Continuing Operations | $-4,176,000 | $-4,679,000 | $-35,140,000 | $-37,730,000 |
| Repayment Of Debt | - | $0 | $-18,105,000 | $-8,333,000 |
| Net Issuance Payments Of Debt | - | $0 | $-18,105,000 | $-8,333,000 |
| Net Long Term Debt Issuance | - | $0 | $-18,105,000 | $-8,333,000 |
| Long Term Debt Payments | - | $0 | $-18,105,000 | $-8,333,000 |
| Sale Of PPE | - | $0 | $1,543,000 | $23,000 |
| Change In Other Current Liabilities | - | $0 | $-138,000 | $-542,000 |
| Asset Impairment Charge | - | $0 | $4,803,000 | $0 |
| Gain Loss On Sale Of PPE | - | $0 | $7,000 | $7,000 |
| Proceeds From Stock Option Exercised | - | - | $0 | $21,000 |
| Common Stock Payments | - | - | $0 | $-45,000 |
| Change In Other Current Assets | - | - | $500,000 | $131,000 |
| Issuance Of Debt | - | - | - | $0 |
| Long Term Debt Issuance | - | - | - | $0 |
Fetched: 2026-06-13